key: cord-0728013-reg78fim
authors: Schiano di Cola, Francesca; Caratozzolo, Salvatore; Liberini, Paolo; Padovani, Alessandro; Rao, Renata
title: CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
date: 2022-01-08
journal: J Neurol
DOI: 10.1007/s00415-021-10946-3
sha: c3f39e6ba76a9b2dd094ebe91bc5aaaf5184c2cf
doc_id: 728013
cord_uid: reg78fim

nan

Monoclonal antibodies targeting CGRP (CGRP-mAbs) have been found to be safe in clinical practice in terms of COVID-19 infection susceptibility and hospitalization/ symptoms [4] . No data are currently available regarding CGRP-mAbs and COVID-19 vaccines.

At the Headache Centre of the Department of Neurology at the University of Brescia/ASST Spedali Civili Brescia, 105 patients with migraine are currently on treatment with CGRP-mAbs, of whom 69 are receiving erenumab (29 patients on erenumab 70 mg/4 weeks, 40 patients on erenumab 140 mg/4 weeks), 28 on galcanezumab and 8 on fremanezumab. Out of 105 patients, 32 underwent COVID-19 vaccinations while on treatment with CGRP-mAbs (8 patients on erenumab 70 mg/4 weeks, 12 on erenumab 140 mg/4 weeks, 8 on galcanezumab, and 2 on fremanezumab). Eighteen patients received the Pfizer/BioNTech Comirnaty vaccine, 11 the Astra-Zeneca/Vaxzevria and 3 the Moderna/ mRNA-1273. All patients who received the Astra-Zeneca/ Vaxzevria vaccine only received the first dose, whereas all others received the full two vaccine administrations. A minimum of 10-14 days between CGRP-mAbs administration and COVID-19 vaccination was suggested. However, some patients did not comply to such recommendations. In particular, five patients waited, on average, less than 5 days between CGRP-mAbs administration and COVID-19 vaccination. None of our patients reported any serious adverse event regarding the vaccination, with most (18 patients) only reporting mild fever and fatigue. Six patients reported a temporary worsening of their usual headache, both in terms of intensity and frequency, lasting, on average, between 1 and 4 days. Side effects distribution was not affected by the type of CGRP-mAbs or vaccine, or by the time lapse between treatment administration and vaccination. CGRP-mAbs long-term efficacy was not affected. No patient reported COVID-19 infection following the vaccination.

Altogether, in our experience, no particular safety or efficacy issues concerning the interaction between CGRP-mAbs and COVID-19 vaccines arose since the beginning of mass vaccination in January 2021. Given the cerebrovascular concerns that have accompanied both CGRP-mAbs and COVID-19 vaccines, together with the high volume of patients on treatment with CGRP-mAbs that will have to be vaccinated, we believe this preliminary report to be extremely helpful for neurologists and physicians in general.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by FSC, SC and PL. The first draft of the manuscript was written by FSC and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

The authors did not receive support from any organization for the submitted work.

Availability of data and materials The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

The authors have no financial or proprietary interests in any material discussed in this article.

Ethics approval Approval was obtained by the local ethics committee of the ASST Spedali Civili Hospital, Brescia (NP 3949, approved August 10, 2020). Consent to participate Verbal informed consent was obtained prior to the interview.

The safety of COVID-19 mRNA vaccines: a review

COVID-19: insights into potential vaccines

Modulation of immune responses by the neuropeptide CGRP

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications